Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has signed a long-term license agreement with Dey Pharma, a specialty division of Mylan, for exclusive marketing and distribution rights of EpiPen (epinephrine) auto-injector in Europe.
Subscribe to our email newsletter
EpiPen is used for emergency treatment of severe allergic reactions (anaphylaxis).
The distribution rights to EpiPen for Europe will be transferred to Meda from current distributors.
As part of the agreement with Dey, Meda will pay a combination of up-front and milestone payments totaling a mid-single million EUR figure.
Meda AB CEO Anders Lonner said EpiPen strengthens their allergy franchise in Europe, and they look forward to working closely with Dey to ensure that this important and life-saving product is accessible to those who are at-risk of an allergic emergency.
Dey Pharma president Carolyn Myers said its been long known and understood that one of their primary objectives is to expand the growth and breadth of their EpiPen franchise.
"After a careful and thorough analysis, we are extremely pleased to partner with Meda, a company with a strong and proven expertise in the allergy category as well as an expansive pan-European marketing platform," Myers said.
"This collaboration strategically positions us to grow the EpiPen franchise and expand access to this important product in Europe. Many Europeans are at risk of allergic emergency, some of whom don’t even know it."